OBJECTIVES: Assess the clinical effect of clostridial collagenase ointment (CCO) relative to undifferentiated wound dressings in the outpatient care setting for the treatment of venous leg ulcers (VLU). METHODS: Retrospective de-identified electronic medical records from 2007-2013 were extracted from the Intellicure Limited Data Set (I-LDS). The I-LDS extracts records from 96 hospital-based outpatient wound centers. A propensity score model using a 3 to 1 nearest neighbor matching approach was performed to test for treatment effect and adjust for covariance between that received CCO and wounds treated with undifferentiated wound dressings. RESULTS: A total of 9,314 patients, 22,312 wounds, and 186,023 visits for VLU were identified. The majority of patients was female (51.9%) with an average age of 61.6 (SD= 17.7). Approximately 21.3% had a history of hypertension, 8.3% had a history of venous insufficiency with diabetes, and 2.5% received immunosuppressive agents. The mean wound surface area was 7.9cm2 (SD= 14.4) . The average wound age was 8.5 months (SD= 27.8) and the average treatment duration was 2.9 months (SD= 4.9). Of the 22,312 wounds, approximately 13.2% received CCO (n= 2,954). The average number of CCO tubes used by patients was 2.6 (SD = 1.2). The average total visits where CCO was administered was 5.6 (SD = 16.2) and the average days of use with CCO was 12.3 (SD = 41.3). VLUs treated with CCO were significantly more likely (p< 0.005) to improve over the course of therapy relative to wounds treated with undifferentiated wound dressings alone. CONCLUSIONS: This analysis indicates that CCO provides a clinical benefit in the management of VLUs. Over the course of therapy VLUs treated with CCO demonstrate greater clinical improvement than VLUs treated with undifferentiated wound dressings.
PIN16 relatIve effICaCy of sImePrevIr (smv) versus telaPrevIr (tPv) IN the treatmeNt of NaÏve geNotyPe 1 ChroNIC hePatItIs C PatIeNts, Based oN INdIreCt ComParIsoN usINg PatIeNt-level ClINICal trIal data
Diels J 1 , Thilakarathne P 2 , Van Sanden S 1 , Sbarigia U 3 , Mehnert A 4 1 Janssen Research & Development, Beerse, Belgium, 2 Janssen Infectious Diseases BVBA, Beerse, Belgium, 3 Janssen Global Services, Beerse, Belgium, 4 Janssen EMEA, Beerse, Belgium OBJECTIVES: To indirectly estimate the relative treatment effect of 12 weeks of treatment with SMV versus TPV in combination with response-guided background therapy of 24/48 weeks of Peginterferon/ribavirine (PR) in previously untreated patients with genotype 1 chronic hepatitis C virus infection, using patient-level data from the pivotal phase III-trials. METHODS: Patient-level data from three phase 3 trials in treatment-naive patients were pooled: ADVANCE (12 weeks of TPV-treatment (T12PR24/48)) and QUEST 1&2 (12 weeks of SMV-treatment (SMV12PR24/48) (with PR24/48 meaning response-guided duration of PR of 24 or 48 weeks). To adjust for potential differences in patient characteristics across both trials, an adjusted odds ratio (OR) for reaching sustained viral response at week 24 (SVR24) was estimated for a multivariate logistic regression model, including genotype (G1a vs G1b), liver status (F0-2 vs F3-4), race (white, black, other), viral load (< 273K/273-< 800K/800-< 1200K/≥ 1200K IU/ml), age (≤ 45/45< -≤ 65/> 65), gender and BMI (< 25/25-< 30/30+) as baseline covariates. As a sensitivity analysis, a similar analysis was generated excluding SMV-G1a patients with Q80Kpolymorphism. RESULTS: Patient numbers for T12PR24/48 and SMV12PR24/48 were 363 and 521 respectively. 16.3% (n= 85) of SMV-patients were G1a with Q80Kpolymorphism. Overall, G1a (OR vs 1b = 0.75, p= 0.01), peg-interferon alpha-2b (OR vs peg-interferon alpha-2a = 0.60, p= 0.03), F3-4 liver status (OR vs F0-F2= 0.48, p< 0.0001), black race (OR vs white race = 0.56, p< 0.001) and viral load ≥ 1200K (OR vs < 273K = 0.28, p< 0.0001) were significantly associated with lower SVR24-rates. The observed SVR24-rates were 75% (TVR) versus 80% (SMV) (unadjusted OR= 0.75). The adjusted OR for T12PR24/48 to reach SVR24 compared to SMV12PR24/48 was 0.64 [95% CI: 0.46;0.91] (p= 0.0113). When excluding Q80K-positive patients, the adjusted OR was 0.45 [0.31;0.67] (p< 0.0001). CONCLUSIONS: In absence of H2H-comparison of telaprevir versus simeprevir in treatment-naive patients, an adjusted indirect commonly used antibiotics to manage cSSSI (vancomycin, linezolid, daptomycin, tigecycline) . METHODS: This retrospective study was conducted using the Premier's Perspective Comparative Database (2010 Database ( -2013 , which includes over 170 million inpatient records from ~500 hospitals in the US. Hospitalization records for adults (≥ 18 years) with a diagnosis of cSSSI (identified using ICD-9-CM codes) were selected. cSSSI-related hospitalization records with evidence of intravenous ceftaroline, vancomycin, daptomycin, linezolid or tigecycline were included. Using four separate logistic regression models propensity scores were estimated and patients in ceftaroline group were matched with patients in vancomycin, daptomycin, linezolid and tigecycline groups separately. Outcomes including LOS, inpatient costs and in-hospital mortality were compared among patients in ceftaroline group with the 4 other antibiotic groups using unadjusted (t-test and chi-square tests) tests. RESULTS: The sample sizes in the matched cohorts were as follows: a) ceftaroline/ vancomycin n= 2,834 (each group); b) ceftaroline/daptomycin n= 2,651; c) ceftaroline/tigecycline n= 2,606; d) ceftaroline/ linezolid n= 2,554. Mean duration for the study antibiotics ranged from 3.9 (vancomycin) to 4.6 (tigecycline) days. Average LOS and inpatients costs were significantly (all P-values < 0.001) lower among patents in the ceftaroline group compared with patients in the vancomycin (mean LOS: 5.1 vs. 5.6;costs: $8,051 vs. $10,089), linezolid (LOS: 5.1 vs. 6.4;costs: $8,081 vs. $12,020), daptomycin (LOS: 5.0 vs. 6.3;costs: $7,824 vs. $10,227), tigecycline (LOS: 5.2 vs. 6.1;costs: $8,264 vs. $11,353) groups. In-hospital mortality rate was ~1% for ceftaroline, vancomycin, tigecycline and daptomycin groups (except linezolid group 2%). CONCLUSIONS: Previously two-large global clinical trials (CANVAS 1 and 2) confirmed clinical efficacy of ceftaroline in-comparison with vancomycin (standard-of-care) among patients with cSSSI. The current study serves as an initial-step towards confirming real-world effectiveness of ceftaroline in comparison with other commonly used antibiotics for cSSSI.
PIN12 health ImPaCt of trIvaleNt, trIvaleNt hIgh dose aNd QuadrIvaleNt INflueNza vaCCINes IN older adults IN oNtarIo, CaNada
Cheng X. 1 , Roïz J. 2 1 City University London, London, UK, 2 Creativ-Ceutical, London, UK OBJECTIVES: New influenza vaccines were developed to improve vaccine effectiveness by expanding influenza B coverage and boosting hemagglutinin (HA) concentration. This research aims to assess the health impact of the new vaccines -high dose (HD) and quadrivalent influenza vaccines (IIV4), instead of IIV3, in adults aged 65 and older under Ontario's Universal Influenza Immunization Program (UIIP). METHODS: An analytical model of one flu season was developed using Ontario's physician visits and ED uses, and Canadian influenza hospitalization and mortality rates with three age cohorts (age 65-74, 75-84, and 85 and above) at two levels of health risks (high and low). Ontario's demographic data was from Statistics Canada. Vaccine efficacy and effectiveness against health outcomes were based on published studies. Sensitivity analyses with extreme values of all relevant parameters were conducted. RESULTS: Use of HD in place of IIV3 would avert 13,271 influenza cases (range: 4,648-23,161) and 2,483 symptomatic non-consulting cases (range: 690-5,226) annually, and decrease health care utilization significantly -3,818 physician office visits (range: 1,530-5,520), 1,223 emergency department (ED) uses (range: 485-1,786), 772 hospitalizations (range: 442-1,223) and 341 deaths (range 195-537) . These reductions in health outcomes would avoid 857 outpatient antiviral treatments (range: 0-2,192) and eliminate 4,546 days of lost productivity (range: 1,387-10,054) among Ontario's elderly residents a year. IIV4 also showed a reduction in influenza-related health outcomes -4,900 influenza cases (range: 3,364-11,817), 1,178 symptomatic non-consulting cases (range: 499-2,665), with 102 hospitalizations (range: 51-175) and 33 deaths (range 17-57) avoided annually; as a result, 1,623 (623-3,928) work days loss were prevented. CONCLUSIONS: Although potential net health impact would fluctuate annually depending on the variability of influenza viruses, both HD and IIV4 are expected to attain significant to modest reductions in influenza-associated morbidity and mortality in seniors. Those findings were proven to be robust in sensitivity analyses. Tang L. Suzhou Municipal Hospital, Suzhou, China OBJECTIVES: Analyze the relationship of clinical efficacy and trough concentration of Vancomycin treatment on Neonatal Bacterial Sepsis according to the high trough concentration standards. METHODS: Totally 73 neonates with bacterial sepsis were selected in our hospital. Their clinical information,labotatory results and pathogens were collected. Statistical analysis of the clinical efficacy, bacterial clearance rate and plasma concentration data after vancomycin treatment. RESULTS: The clinical total effective rate and bacterial clearance rate were 86.30% and 91.78%. The average trough concentration of vancomycin was(12.57±6.83)mg·L-1 . The rate of reaching the high trough concentration standards was only 41.1%. Compared to < 10mg·L-1, the bacterial clearance rate and clinical efficacy of trough concentration in 10-20mg·L-1 were much higher (P= 0.013, P= 0.001). 24 cases adjusted the dose according to the initial concentration data, but only 13 cases(54.17%)'s trough concentrations were in the standard range. CONCLUSIONS: Clinical efficacy of Vancomycin has a good correlation with trough concentration. But the rate of reaching the high trough concentration standard was low and TDM is needed for individualized therapy regimen. 
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